DE69708629T2 - Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren - Google Patents

Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren

Info

Publication number
DE69708629T2
DE69708629T2 DE69708629T DE69708629T DE69708629T2 DE 69708629 T2 DE69708629 T2 DE 69708629T2 DE 69708629 T DE69708629 T DE 69708629T DE 69708629 T DE69708629 T DE 69708629T DE 69708629 T2 DE69708629 T2 DE 69708629T2
Authority
DE
Germany
Prior art keywords
alkyloxyamine
inhibitors
protein kinase
fluorenone derivatives
substituted fluorenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69708629T
Other languages
English (en)
Other versions
DE69708629D1 (de
Inventor
D Jones
L Ciske
J Dinerstein
A Diekema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27096988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69708629(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69708629D1 publication Critical patent/DE69708629D1/de
Publication of DE69708629T2 publication Critical patent/DE69708629T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/24—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
DE69708629T 1996-05-30 1997-04-24 Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren Expired - Lifetime DE69708629T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65558496A 1996-05-30 1996-05-30
US65553796A 1996-05-30 1996-05-30
PCT/US1997/006602 WO1997045397A1 (en) 1996-05-30 1997-04-24 Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors

Publications (2)

Publication Number Publication Date
DE69708629D1 DE69708629D1 (de) 2002-01-10
DE69708629T2 true DE69708629T2 (de) 2002-08-01

Family

ID=27096988

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69708629T Expired - Lifetime DE69708629T2 (de) 1996-05-30 1997-04-24 Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren

Country Status (18)

Country Link
EP (1) EP0906268B1 (de)
JP (1) JP3897363B2 (de)
CN (1) CN1160309C (de)
AR (1) AR008375A1 (de)
AT (1) ATE209626T1 (de)
AU (1) AU737073B2 (de)
BR (1) BR9709406B1 (de)
CA (1) CA2257136C (de)
DE (1) DE69708629T2 (de)
DK (1) DK0906268T3 (de)
ES (1) ES2170390T3 (de)
HK (1) HK1019147A1 (de)
HU (1) HUP9901621A3 (de)
IL (1) IL126873A (de)
NO (1) NO312457B1 (de)
NZ (1) NZ332597A (de)
PT (1) PT906268E (de)
WO (1) WO1997045397A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
DE19908504C2 (de) * 1999-02-26 2003-04-30 Boehringer Ingelheim Pharma Großtechnisches Verfahren zur Herstellung von Derivaten der Biphenyl-2-carbonsäure durch Verseifen eines (2-Oxazolinyl)-2-biphenyl-Derivats mit Salzsäure
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
EP1309563B1 (de) 2000-08-18 2005-05-11 Agouron Pharmaceuticals, Inc. Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
RU2012133148A (ru) * 2010-01-11 2014-02-20 Хилор Лтд. Способ лечения воспалительного заболевания и расстройства
CN103204781B (zh) * 2013-03-14 2015-04-01 武汉大学 2,7–二取代芴酮衍生物及其制备方法与应用
CN109053435A (zh) * 2018-08-03 2018-12-21 上海华堇生物技术有限责任公司 2,3-二甲氧基苯甲酰氯的制备方法
CN115590964A (zh) * 2022-09-14 2023-01-13 苏州大学（Cn） 蛋白激酶c抑制剂在制备抗肿瘤转移药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL33573A (en) * 1968-12-30 1973-10-25 Richardson Merrell Inc Bis-basic ethers and thioethers of fluorenone,fluorenol and fluorene
US5034384A (en) * 1990-08-01 1991-07-23 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem antibacterial agents

Also Published As

Publication number Publication date
AR008375A1 (es) 2000-01-19
JP3897363B2 (ja) 2007-03-22
NO985577D0 (no) 1998-11-27
DK0906268T3 (da) 2002-03-18
HUP9901621A3 (en) 2002-01-28
ES2170390T3 (es) 2002-08-01
CN1160309C (zh) 2004-08-04
AU737073B2 (en) 2001-08-09
BR9709406A (pt) 1999-08-10
PT906268E (pt) 2002-05-31
CA2257136C (en) 2004-07-20
HUP9901621A2 (hu) 1999-08-30
CA2257136A1 (en) 1997-12-04
NO312457B1 (no) 2002-05-13
WO1997045397A1 (en) 1997-12-04
EP0906268A1 (de) 1999-04-07
CN1220660A (zh) 1999-06-23
EP0906268B1 (de) 2001-11-28
BR9709406B1 (pt) 2009-05-05
NO985577L (no) 1999-01-27
IL126873A (en) 2005-09-25
IL126873A0 (en) 1999-09-22
NZ332597A (en) 2000-08-25
JP2000511528A (ja) 2000-09-05
DE69708629D1 (de) 2002-01-10
AU2736597A (en) 1998-01-05
ATE209626T1 (de) 2001-12-15
HK1019147A1 (en) 2000-01-14

Similar Documents

Publication Publication Date Title
DE69836346D1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
ATE202347T1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
DE69826662D1 (de) 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE59712887D1 (de) Substituierte phenylketoenole und ihre verwendung als schädlingsbekämpfungsmittel
ATE251612T1 (de) 6-phenylpyridyl-2-amin-derivate verwendbar als nos-inhibitoren
DE59710422D1 (de) Acylmercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE69332898T2 (de) 4-Carboxamidopiperidinderivate und ihre Verwendung als Neurokinin Antagonisten
DE59503881D1 (de) Heterospiroverbindungen und ihre verwendung als elektrolumineszenzmaterialien
DE59710580D1 (de) Thiocyano-triazolyl-derivate und ihre verwendung als mikrobizide
ATE277902T1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
DE69706823T2 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren
DE69708629D1 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
DE69510228D1 (de) Piperidinessigsäurederivate und ihre verwendung als fibrinogenantagonistmittel
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE69717647D1 (de) 3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
DE69620914D1 (de) Perfluoralkoxycycloalkancarbonylfluorid-zusammensetzungen und ihre verwendung
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
DE59806523D1 (de) Substituierte heterocyclische Benzocycloalkene und ihre Verwendung als analgetisch wirksame Substanzen
DE69821988D1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
DE59711502D1 (de) Oximderivate und ihre verwendung als fungizide
DE59510203D1 (de) Aminosäure-Derivate und ihre Verwendung als Schädlingsbekämpfungsmittel
DE69732095D1 (de) Ionomerzusammensetzung und ihre verwendung
DE69412083D1 (de) Phenylpyrrolderivate und ihre verwendung als antipsychotika
DE69718850D1 (de) Heterocyclische N-Acetonylbenzamide und ihre Verwendung als Fungizide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DEL., US

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US